ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Interview With AACR’s Margaret Foti: “The Meeting Wouldn’t Have Been The Same.”

April 4, 2003

Foundation Supports Chicago Researchers

September 10, 1993

Cancer Policy: Coffey Letter Lists Research Initiatives That Justify Increase

December 19, 1997

Bepler To Lead Karmanos Cancer Institute

January 29, 2010

Revive Comprehensive Program, But Don’t Tie It to Grant Review, Center Executive Agrees

July 29, 1988

Capizzi Succeeds Spurr as Director Of Bowman Gray Cancer Center

September 10, 1982